Research programme: cancer therapeutics - Access Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Access Pharmaceuticals

Alternative Names: Alchemix; Angiolix; HuMc-3 mAb; Prodrax

Latest Information Update: 01 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator De Montfort University; Immunodex; University of London School of Pharmacy
  • Developer Access Pharmaceuticals; University of Bradford
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; DNA intercalators; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 01 Feb 2011 No development reported - Preclinical for Solid tumours in United Kingdom (Parenteral)
  • 01 Feb 2011 No development reported - Preclinical for Solid tumours in USA (Parenteral)
  • 02 Oct 2008 Pharmacodynamics data from preclinical studies on Angiolix® in breast cancer released by Access Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top